Therapeutic Outcomes of High Dose-Dexamethasone versus Prednisolone + Azathioprine, Rituximab, Eltrombopag, and Romiplostim Strategies in Persistent, Chronic, Refractory, and Relapsed Immune Thrombocytopenia Patients

• DOI: 10.3390/ph16091215
• Publication Date: 2023-08-29T12:26:52Z
• Authors: Eman Mostafa Hamed; Ahmed R. N. Ibrahim; Mohamed Hussein M...; Ahmed M. Khalaf; Doaa Mohamed El D...; Marwa O. Elgendy; Haitham Saeed; Heba F. Salem; Hoda Rabea
• Keywords: Eltrombopag; Romiplostim; Prednisolone; Refractory (planetary science)

Primary immune thrombocytopenia (ITP) is an inflammatory autoimmune disease that can be managed with several treatment options. However, there a lack of comparative data on the efficacy these options in different phases disease. This study aimed to evaluate high-dose Dexamethasone (HD-DXM), Prednisolone + Azathioprine, Rituximab, Eltrombopag, and Romiplostim schedules persistent, chronic refractory or relapsed Egyptian ITP patients platelet count ≤30 × 109/L. The primary outcome measure was sustained increase counts over 50 109/L for additional 12 months without regimens. also identify suitable regimen long remission duration each phase ITP. Azathioprine significantly more effective achieving overall response persistent than Romiplostim, Dexamethasone, Rituximab. (90.9% vs. 66.6, [Odds ratio, OR: 5; confidence interval, CI 95% (0.866-28.86)], 45%, [OR: 0.082, (0.015-0.448)] and, 25%, 30, (4.24-211.8)], respectively, p-value < 0.01). Eltrombopag durable HD-DXM, Prednisolone; (80% compared 32.2% 0.119, (0.035-0.410)], 22.2% [OR:0.071, (0.011-0.455)], 18.1% 0.056, (0.009-0.342)], Finally, following HD-DXM showed highest percentage complete treatment-free survival times at least 330 days. These findings could help clinicians choose most appropriate their based trial registered clinicaltrials.gov registration number NCT05861297.